Germinal epimutation of Fragile Histidine Triad (FHIT) gene is associated with progression to acute and chronic adult T-cell leukemia diseases

Marcia Bellon (1) , Izabela Bialuk (2) , Veronica Galli (2) , Xue-Tao Bai (3) , Lourdes Farre (4) , Achilea Bittencourt (5) , Ambroise Marçais (6) , Michael Petrus (2) , Lee Ratner (7) , Thomas Waldmann (2) , Vahid Asnafi (6) , Antoine Gessain (8) , Masao Matsuoka (9, 10) , Genoveffa Franchini (2) , Olivier Hermine (6) , Toshiki Watanabe (11) , Christophe Nicot (1)

1 University of Kansas Medical Center [Kansas City, KS, USA]
2 NCI-NIH - National Cancer Institute [Bethesda]
3 OSU - Ohio State University [Columbus]
4 Hospitalet de Llobregat
5 UFBA - Universidade Federal da Bahia
6 INEM - UM 111 (UMR 8253 / U1151) - Institut Necker Enfants-Malades
7 WUSTL - Washington University in Saint Louis
8 EPVO (UMR_3569 / U-Pasteur_3) - Epidémiologie et Physiopathologie des Virus Oncogènes
9 Kyoto University
10 Kumamoto University
11 UTokyo - The University of Tokyo

Background Human T cell Leukemia virus type 1 (HTLV-I) is etiologically linked to adult T cell leukemia/lymphoma (ATL) and an inflammatory neurodegenerative disease called HTLV-I-associated myelopathy or tropical spastic paraparesis (HAM/TSP). The exact genetic or epigenetic events and/or environmental factors that influence the development of ATL, or HAM/TSP diseases are largely unknown. The tumor suppressor gene, Fragile Histidine Triad Diadenosine Triphosphatase (FHIT), is frequently lost in cancer through epigenetic modifications and/or deletion. FHIT is a tumor suppressor acting as genome caretaker by regulating cellular DNA repair. Indeed, FHIT loss leads to replicative stress and accumulation of double DNA strand breaks. Therefore, loss of FHIT expression plays a key role in cellular transformation. Methods Here, we studied over 400 samples from HTLV-I-infected individuals with ATL, TSP/HAM, or asymptomatic carriers (AC) for FHIT loss and expression. We examined the epigenetic status of FHIT through methylation specific PCR and bisulfite sequencing; and correlated these results to FHIT expression in patient samples. Results We found that epigenetic alteration of FHIT is specifically found in chronic and acute ATL but is absent in asymptomatic HTLV-I carriers and TSP/HAM patients’ samples. Furthermore, the extent of FHIT methylation in ATL patients was quantitatively comparable in virus-infected and virus non-infected cells. We also found that longitudinal HTLV-I carriers that progressed to smoldering ATL and descendants of ATL patients harbor FHIT methylation. Conclusions These results suggest that germinal epigenetic mutation of FHIT represents a preexisting mark predisposing to the development of ATL diseases. These findings have important clinical implications as patients with acute ATL are rarely cured. Our study suggests an alternative strategy to the current “wait and see approach” in that early screening of HTLV-I-infected individuals for germinal epimutation of FHIT and early treatment may offer significant clinical benefits.

Mots clés: ATL; ATLL; Cancer; Epigenetic; Epimutation; FHIT; HAM; HTLV-1; Leukemia; Lymphoma; Methylation; TSP; TSP/HAM; Tax

Domaines: Sciences du Vivant [q-bio]

Marcia Bellon, Izabela Bialuk, Veronica Galli, Xue-Tao Bai, Lourdes Farre, et al.. Germinal epimutation of Fragile Histidine Triad (FHIT) gene is associated with progression to acute and chronic adult T-cell leukemia diseases. Molecular Cancer, 2021, 20 (1), pp.86. ⟨10.1186/s12943-021-01370-2⟩. ⟨pasteur-04079419⟩